Jinshi data news on January 22nd, Haiwang Biology expects the net profit attributed to shareholders of the listed company in 2024 to be a loss of 950 million to 1.2 billion yuan, a decrease of 1.69 billion yuan from the same period last year; the net profit after deducting non-recurring gains and losses is expected to be a loss of 1 billion to 1.25 billion yuan, a decrease of 1.74 billion yuan from the same period last year; the basic earnings per share is expected to be a loss of 0.3611 yuan/share to 0.4561 yuan/share, a decrease of 0.6423 yuan/share from the same period last year. Operating income is expected to be 2.8 billion to 3.2 billion yuan, a decrease of 36.42 billion yuan from the same period last year. The main reasons are the decline in main business income, provision for impairment of goodwill of about 400 million to 570 million yuan, and provision for impairment of accounts receivable of about 230 million to 330 million yuan.
Disclaimer: The information on this page may come from third parties and does not represent the views or opinions of Gate. The content displayed on this page is for reference only and does not constitute any financial, investment, or legal advice. Gate does not guarantee the accuracy or completeness of the information and shall not be liable for any losses arising from the use of this information. Virtual asset investments carry high risks and are subject to significant price volatility. You may lose all of your invested principal. Please fully understand the relevant risks and make prudent decisions based on your own financial situation and risk tolerance. For details, please refer to
Disclaimer.
